Shandong Weigao Group Medical Polymer Company Limited
Shandong Weigao Group Medical Polymer Company Limited, commonly referred to as Weigao, is a leading player in the medical device industry, headquartered in Shandong, China. Established in 1988, the company has grown significantly, expanding its operations across various regions, including Asia, Europe, and North America. Weigao specialises in the development and manufacturing of high-quality medical polymer products, including intravenous (IV) products, surgical instruments, and diagnostic devices. Their commitment to innovation and quality has positioned them as a trusted supplier in the healthcare sector. Notably, Weigao has achieved several milestones, including numerous certifications and awards that underscore its dedication to excellence and safety in medical technology. With a strong market presence, Weigao continues to enhance patient care through its advanced medical solutions.
DitchCarbon Score
How does Shandong Weigao Group Medical Polymer Company Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shandong Weigao Group Medical Polymer Company Limited's score of 30 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shandong Weigao Group Medical Polymer Company Limited's reported carbon emissions
In 2024, Shandong Weigao Group Medical Polymer Company Limited reported total emissions of approximately 126,139,020 kg CO2e, with significant contributions from Scope 2 emissions, including about 41,295,430 kg CO2e from purchased steam and approximately 81,747,340 kg CO2e from purchased electricity. In 2023, the company recorded Scope 1 emissions of about 2,704,870 kg CO2e, alongside Scope 2 emissions of approximately 99,528,780 kg CO2e. The total emissions for that year were not explicitly stated but can be inferred to be around 102,233,650 kg CO2e when combining both scopes. For 2022, the reported emissions included approximately 2,978,680 kg CO2e from Scope 1 and about 101,426,260 kg CO2e from Scope 2, leading to a total of around 104,404,940 kg CO2e. Despite these figures, Shandong Weigao has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint, nor have they committed to any science-based targets. The absence of detailed climate commitments suggests a need for further transparency and action in addressing their environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 2,978,680 | 0,000,000 | - |
| Scope 2 | 101,426,260 | 00,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shandong Weigao Group Medical Polymer Company Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
